{
    "clinical_study": {
        "@rank": "144808", 
        "arm_group": [
            {
                "arm_group_label": "ALA", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if Levulan PDT is safe and effective in the\n      treatment of actinic keratoses on the upper arms and hands"
        }, 
        "brief_title": "Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Actinic Keratosis", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Four to fifteen Grade 1/2 AKs on one upper extremity\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  grade 3 and/or atypical >1cm AKs within Treatment Area\n\n          -  history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or\n             photodermatosis\n\n          -  lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated\n             skin cancers within the Treatment Area\n\n          -  skin pathology or condition which could interfere with the evaluation of the test\n             product or requires the use of interfering topical or systemic therapy\n\n          -  Subject is immunosuppressed\n\n          -  unsuccessful outcome from previous ALA-PDT therapy\n\n          -  currently enrolled in an investigational drug or device study\n\n          -  has received an investigational drug or been treated with an investigational device\n             within 30 days prior to the initiation of treatment\n\n          -  known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl\n             alcohol, laureth 4, polyethylene glycol)\n\n          -  use of the following topical preparations on the extremity to be treated:\n\n               -  Keratolytics including urea (greater than 5%), alpha hydroxyacids [e.g.glycolic\n                  acid, lactic acid, etc. greater than 5%], salicylic acid (greater than 2%)\n                  within 2 days of initiation of treatment.\n\n               -  Cryotherapy within 2 weeks of initiation of treatment\n\n               -  Retinoids, including tazarotene, adapalene, tretinoin, within 4 weeks of\n                  initiation of treatment.\n\n               -  Microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-FU,\n                  diclofenac, ingenol mebutate, imiquimod or other topical treatments for AK\n                  within 8 weeks of initiation of treatment.\n\n          -  use of systemic retinoid therapy within 6 months of initiation of treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "260", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137785", 
            "org_study_id": "CP0108"
        }, 
        "intervention": [
            {
                "arm_group_label": "ALA", 
                "description": "20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light", 
                "intervention_name": "Aminolevulinic Acid (ALA)", 
                "intervention_type": "Drug", 
                "other_name": "Levulan Kerastick"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "description": "Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light", 
                "intervention_name": "Topical Solution Vehicle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ALA", 
                    "Vehicle"
                ], 
                "description": "10 J/cm2 blue light delivered at 10mW/cm2", 
                "intervention_name": "BLU-U Blue Light Photodynamic Therapy Illuminator", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aminolevulinic Acid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Actinic Keratosis", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "GalynaC@centerforderm.com", 
                    "last_name": "Galyna Cavallaro", 
                    "phone": "510-797-0140"
                }, 
                "facility": {
                    "address": {
                        "city": "Fremont", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94538"
                    }, 
                    "name": "Center For Dermatology Clinical Research, Inc."
                }, 
                "investigator": {
                    "last_name": "Sunil Dhawan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fshafiq@ucsd.edu", 
                    "last_name": "Faiza Shafiq", 
                    "phone": "858-657-1697"
                }, 
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92122"
                    }, 
                    "name": "UCSD Dermatology"
                }, 
                "investigator": {
                    "last_name": "Brian Jiang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andrew Frisina", 
                    "phone": "305-933-6716"
                }, 
                "facility": {
                    "address": {
                        "city": "Aventura", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33180"
                    }, 
                    "name": "Center for Clinical and Cosmetic Research"
                }, 
                "investigator": {
                    "last_name": "Brian Berman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Carols Werner", 
                    "phone": "813-948-7550"
                }, 
                "facility": {
                    "address": {
                        "city": "Brandon", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33609"
                    }, 
                    "name": "MOORE Clinical Research, Inc"
                }, 
                "investigator": {
                    "last_name": "Susan Barker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "spencerclinicalservices@hotmail.com", 
                    "last_name": "Juliana Accoily", 
                    "phone": "727-572-1333"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33716"
                    }, 
                    "name": "Spencer Clinical Services"
                }, 
                "investigator": {
                    "last_name": "James Spencer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Matt Cholewa", 
                    "phone": "847-392-5440"
                }, 
                "facility": {
                    "address": {
                        "city": "Arlington Heights", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60005"
                    }, 
                    "name": "Altman Dermatology Associates"
                }, 
                "investigator": {
                    "last_name": "Michael Bukhalo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mhoffman@shideler.com", 
                    "last_name": "Mary Hoffman"
                }, 
                "facility": {
                    "address": {
                        "city": "Carmel", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46032"
                    }, 
                    "name": "Shideler Clinical Research Center"
                }, 
                "investigator": {
                    "last_name": "Stephen Shideler, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "keads@indianatrials.com", 
                    "last_name": "Kimmie Eads", 
                    "phone": "317-837-6082"
                }, 
                "facility": {
                    "address": {
                        "city": "Plainfield", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46168"
                    }, 
                    "name": "The Indiana Clinical Trials Center, PC"
                }, 
                "investigator": {
                    "last_name": "Scott Guenthner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "droberts@associatedskincare.com", 
                    "last_name": "Donna Roberts", 
                    "phone": "763-571-4200"
                }, 
                "facility": {
                    "address": {
                        "city": "Fridley", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55432"
                    }, 
                    "name": "Minnesota Clinical Study Center"
                }, 
                "investigator": {
                    "last_name": "Steven Kempers, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Racheal Manhart", 
                    "phone": "503-226-3376"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Oregon Dermatology and Research Center"
                }, 
                "investigator": {
                    "last_name": "Pheobe Rich, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jscott@js-studies.com", 
                    "last_name": "Jeremy Scott", 
                    "phone": "979-774-5933"
                }, 
                "facility": {
                    "address": {
                        "city": "College Station", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77845"
                    }, 
                    "name": "J&S Studies, Inc"
                }, 
                "investigator": {
                    "last_name": "Terry Jones, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "aherod@sba-skincare.com", 
                    "last_name": "Amanda Herod", 
                    "phone": "713-985-0210"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77056"
                    }, 
                    "name": "Suzanne Bruce and Associates, P.A.,The Center for Skin Research"
                }, 
                "investigator": {
                    "last_name": "Suzanne Bruce, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "erivera@vcrinc.org", 
                    "last_name": "Erin Rivera", 
                    "phone": "757-625-0151"
                }, 
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23507"
                    }, 
                    "name": "Virginia Clinical Research, Inc."
                }, 
                "investigator": {
                    "last_name": "Robert Pariser, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities", 
        "other_outcome": [
            {
                "description": "HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas", 
                "measure": "Hyperpigmentation", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas", 
                "measure": "Hyperpigmentation", 
                "safety_issue": "Yes", 
                "time_frame": "24-48 hours after PDT #1"
            }, 
            {
                "description": "HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas", 
                "measure": "Hyperpigmentation", 
                "safety_issue": "Yes", 
                "time_frame": "2 Weeks after PDT #1"
            }, 
            {
                "description": "HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas", 
                "measure": "Hyperpigmentation", 
                "safety_issue": "Yes", 
                "time_frame": "4 Weeks after PDT #1"
            }, 
            {
                "description": "HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas", 
                "measure": "Hyperpigmentation", 
                "safety_issue": "Yes", 
                "time_frame": "8 Weeks after PDT #1"
            }, 
            {
                "description": "HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas", 
                "measure": "Hyperpigmentation", 
                "safety_issue": "Yes", 
                "time_frame": "12 Weeks after PDT #1"
            }, 
            {
                "description": "HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation", 
                "measure": "Hypopigmentation", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation", 
                "measure": "Hypopigmentation", 
                "safety_issue": "Yes", 
                "time_frame": "24-48 hours after PDT #1"
            }, 
            {
                "description": "HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation", 
                "measure": "Hypopigmentation", 
                "safety_issue": "Yes", 
                "time_frame": "2 Weeks after PDT #1"
            }, 
            {
                "description": "HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation", 
                "measure": "Hypopigmentation", 
                "safety_issue": "Yes", 
                "time_frame": "4 Weeks after PDT #1"
            }, 
            {
                "description": "HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation", 
                "measure": "Hypopigmentation", 
                "safety_issue": "Yes", 
                "time_frame": "8 Weeks after PDT #1"
            }, 
            {
                "description": "HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation", 
                "measure": "Hypopigmentation", 
                "safety_issue": "Yes", 
                "time_frame": "12 Weeks after PDT #1"
            }, 
            {
                "description": "Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema", 
                "measure": "Erythema", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema", 
                "measure": "Erythema", 
                "safety_issue": "Yes", 
                "time_frame": "5 minutes after PDT #1"
            }, 
            {
                "description": "Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema", 
                "measure": "Erythema", 
                "safety_issue": "Yes", 
                "time_frame": "24-48 hours after PDT #1"
            }, 
            {
                "description": "Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema", 
                "measure": "Erythema", 
                "safety_issue": "Yes", 
                "time_frame": "2 Weeks after PDT #1"
            }, 
            {
                "description": "Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema", 
                "measure": "Erythema", 
                "safety_issue": "Yes", 
                "time_frame": "4 Weeks after PDT #1"
            }, 
            {
                "description": "Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema", 
                "measure": "Erythema", 
                "safety_issue": "Yes", 
                "time_frame": "8 Weeks after PDT #1"
            }, 
            {
                "description": "Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema", 
                "measure": "Erythema", 
                "safety_issue": "Yes", 
                "time_frame": "12 Weeks after PDT #1"
            }, 
            {
                "description": "\ufeffEDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area", 
                "measure": "Edema", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "\ufeffEDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area", 
                "measure": "Edema", 
                "safety_issue": "Yes", 
                "time_frame": "5 minutes after PDT #1"
            }, 
            {
                "description": "\ufeffEDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area", 
                "measure": "Edema", 
                "safety_issue": "Yes", 
                "time_frame": "24-48 hours after PDT #1"
            }, 
            {
                "description": "\ufeffEDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area", 
                "measure": "Edema", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks after PDT #1"
            }, 
            {
                "description": "\ufeffEDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area", 
                "measure": "Edema", 
                "safety_issue": "Yes", 
                "time_frame": "4 Weeks after PDT #1"
            }, 
            {
                "description": "\ufeffEDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area", 
                "measure": "Edema", 
                "safety_issue": "Yes", 
                "time_frame": "8 Weeks after PDT #1"
            }, 
            {
                "description": "\ufeffEDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area", 
                "measure": "Edema", 
                "safety_issue": "Yes", 
                "time_frame": "12 Weeks after PDT #1"
            }, 
            {
                "description": "\ufeffSTINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable", 
                "measure": "Stinging/Burning", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "\ufeffSTINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable", 
                "measure": "Stinging/Burning", 
                "safety_issue": "Yes", 
                "time_frame": "During PDT #1"
            }, 
            {
                "description": "\ufeffSTINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable", 
                "measure": "Stinging/Burning", 
                "safety_issue": "Yes", 
                "time_frame": "5 minutes after PDT #1"
            }, 
            {
                "description": "\ufeffSTINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable", 
                "measure": "Stinging/Burning", 
                "safety_issue": "Yes", 
                "time_frame": "2 Weeks after PDT #1"
            }, 
            {
                "description": "\ufeffSTINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable", 
                "measure": "Stinging/Burning", 
                "safety_issue": "Yes", 
                "time_frame": "4 Weeks after PDT #1"
            }, 
            {
                "description": "\ufeffSTINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable", 
                "measure": "Stinging/Burning", 
                "safety_issue": "Yes", 
                "time_frame": "8 Weeks after PDT #1"
            }, 
            {
                "description": "\ufeffSTINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable", 
                "measure": "Stinging/Burning", 
                "safety_issue": "Yes", 
                "time_frame": "12 Weeks after PDT #1"
            }, 
            {
                "description": "\ufeffSCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling", 
                "measure": "Scaling & Dryness", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "\ufeffSCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling", 
                "measure": "Scaling & Dryness", 
                "safety_issue": "Yes", 
                "time_frame": "24-48 hours after PDT #1"
            }, 
            {
                "description": "\ufeffSCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling", 
                "measure": "Scaling & Dryness", 
                "safety_issue": "Yes", 
                "time_frame": "2 Weeks after PDT #1"
            }, 
            {
                "description": "\ufeffSCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling", 
                "measure": "Scaling & Dryness", 
                "safety_issue": "Yes", 
                "time_frame": "4 Weeks after PDT #1"
            }, 
            {
                "description": "\ufeffSCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling", 
                "measure": "Scaling & Dryness", 
                "safety_issue": "Yes", 
                "time_frame": "8 Weeks after PDT #1"
            }, 
            {
                "description": "\ufeffSCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling", 
                "measure": "Scaling & Dryness", 
                "safety_issue": "Yes", 
                "time_frame": "12 Weeks after PDT #1"
            }, 
            {
                "description": "OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above", 
                "measure": "Oozing/Vesiculation/Crusting", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above", 
                "measure": "Oozing/Vesiculation/Crusting", 
                "safety_issue": "Yes", 
                "time_frame": "24-48 hours after PDT #1"
            }, 
            {
                "description": "OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above", 
                "measure": "Oozing/Vesiculation/Crusting", 
                "safety_issue": "Yes", 
                "time_frame": "2 Weeks after PDT #1"
            }, 
            {
                "description": "OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above", 
                "measure": "Oozing/Vesiculation/Crusting", 
                "safety_issue": "Yes", 
                "time_frame": "4 Weeks after PDT #1"
            }, 
            {
                "description": "OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above", 
                "measure": "Oozing/Vesiculation/Crusting", 
                "safety_issue": "Yes", 
                "time_frame": "8 Weeks after PDT #1"
            }, 
            {
                "description": "OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above", 
                "measure": "Oozing/Vesiculation/Crusting", 
                "safety_issue": "Yes", 
                "time_frame": "12 Weeks after PDT #1"
            }
        ], 
        "overall_contact": {
            "email": "jberg@therapeuticsinc.com", 
            "last_name": "Jim Berg", 
            "phone": "858-571-1800 Ext. 131"
        }, 
        "overall_contact_backup": {
            "email": "danp@therapeuticsinc.com", 
            "last_name": "Dan Piacquadio, MD", 
            "phone": "858-571-1800 Ext. 107"
        }, 
        "overall_official": {
            "affiliation": "DUSA Pharmaceuticals, Inc.", 
            "last_name": "Stuart Marcus, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "proportion of subjects in each treatment group with a count of zero lesions in the Treatment Area", 
            "measure": "Complete Clearance Rate", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137785"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "{1 - [(number of AK lesions at follow-up)/(number of AK lesions at Baseline)]} x 100", 
                "measure": "AK Clearance Rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "description": "{1 - [(number of AK lesions at follow-up)/(number of AK lesions at Baseline)]} x 100", 
                "measure": "AK Clearance Rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 8"
            }, 
            {
                "description": "proportion of subjects in each treatment group with a count of zero lesions in the Treatment Area", 
                "measure": "Complete Clearance Rate", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }, 
            {
                "description": "Subject satisfaction score\n= Excellent (very satisfied)\n= Good (moderately satisfied)\n= Fair (slightly satisfied)\n= Poor (not satisfied at all)", 
                "measure": "Subject Satisfaction Score", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }
        ], 
        "source": "DUSA Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "DUSA Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}